SS-31, also known as Elamipretide, MTP-131, or Bendavia, is a synthetic mitochondria-targeted tetrapeptide developed to improve mitochondrial function by binding to cardiolipin, a phospholipid found exclusively in the inner mitochondrial membrane. Unlike most peptides that act through hormone receptors, SS-31 works directly within mitochondria to improve energy production and reduce oxidative stress.
SS-31 has been investigated for numerous diseases associated with mitochondrial dysfunction, including Barth syndrome, primary mitochondrial myopathy, heart failure, chronic kidney disease, age-related muscle dysfunction, neurodegenerative disease, and retinal disorders.
As of September 2025, elamipretide (brand name Forzinity®) received FDA accelerated approval for the treatment of Barth syndrome in patients weighing at least 30 kg, making it the first FDA-approved mitochondria-targeted therapeutic.
Unlike growth hormone secretagogues or immune peptides, SS-31 acts directly within mitochondria.
Research suggests SS-31:
Rather than acting as a conventional antioxidant, SS-31 appears to improve mitochondrial efficiency by preserving normal mitochondrial membrane architecture and optimizing energy production.
Published research suggests SS-31 may provide several biologic benefits related to mitochondrial function.
Potential benefits may include:
Many of these findings have been demonstrated in animal studies and early human clinical trials. Evidence varies by disease state, and several indications remain investigational.
SS-31 has generally demonstrated a favorable safety profile in clinical trials.
Reported adverse effects include:
Serious adverse reactions have been uncommon in published clinical studies. The most frequently reported side effects in trials leading to FDA approval for Barth syndrome were mild-to-moderate injection-site reactions.
Formal contraindications remain limited because clinical experience is still evolving.
SS-31 should generally be used with caution in patients with:
Patients with complex cardiovascular, renal, neurologic, or mitochondrial disorders should be managed by clinicians experienced in these conditions.
United States
Elamipretide (Forzinity®) received FDA accelerated approval on September 19, 2025 as the first treatment for Barth syndrome in patients weighing at least 30 kg. The approval was based on improvement in knee extensor muscle strength, with a post-marketing confirmatory trial required to verify clinical benefit.
Outside of Barth syndrome, SS-31 is not FDA-approved for:
Most other uses remain investigational.
Human Studies
SS-31 has been evaluated in numerous Phase I, II, and III clinical trials.
Human studies have investigated SS-31 for:
Clinical research has demonstrated:
The strongest current clinical evidence exists for Barth syndrome, which resulted in FDA accelerated approval.
Animal & Preclinical Studies
Extensive laboratory and animal studies have shown that SS-31 may:
Recent mechanistic work demonstrated that SS-31 improves ADP uptake through the adenine nucleotide translocator (ANT), restoring mitochondrial energy production in aged muscle.
Human Studies
Animal & Preclinical Studies
FDA / Regulatory Sources
Review Articles
The information provided on this page is intended for educational and informational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease and should not be considered medical advice.
This content was generated with the assistance of artificial intelligence (AI) and should be reviewed by a qualified medical professional before publication or clinical use. AI-generated medical content may contain errors, omissions, or outdated information.
SS-31 (elamipretide) received FDA accelerated approval in 2025 for the treatment of Barth syndrome. Most other proposed uses remain investigational and are not FDA-approved. Individual results vary, and no specific outcome or benefit can be guaranteed. Patients should consult a qualified healthcare provider before beginning or changing any medical treatment.
R2 Medical Clinic uses medications sourced from compounding pharmacies. Compounded medications are not approved by the U.S. Food and Drug Administration (FDA). Unlike FDA-approved medications, compounded drugs have not undergone FDA review for safety, effectiveness, or efficacy through the FDA drug approval process. While 503B outsourcing facilities are registered with and inspected by the FDA and must comply with Current Good Manufacturing Practice (CGMP) requirements, the compounded medications they produce are not individually approved by the FDA. Similarly, compounded medications prepared by 503A pharmacies are not FDA-approved and are primarily regulated by state boards of pharmacy, with FDA oversight under applicable federal law.
# Kisspeptin